Planned Phase III Trial of Ruxolitinib Plus Standard-of-Care for Patients with COVID-19

Incyte announced that they are working with the FDA to initiate a phase III clinical trial to assess ruxolitinib (Jakafi) plus standard-of-care in patients with coronavirus disease 2019 (COVID-19) induced cytokine storm.

Source: CancerNetwork - April 7, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news